BeyondSpring, Inc. - Ordinary Shares (BYSI) Covered Calls

You can sell covered calls on BeyondSpring, Inc. - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BYSI (prices last updated Fri 4:16 PM ET):

BeyondSpring, Inc. - Ordinary Shares (BYSI) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
3.28 -0.23 3.25 3.38 1.3M - 0.1
Covered Calls For BeyondSpring, Inc. - Ordinary Shares (BYSI)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Feb 18 2.5 0.80 2.58 -3.1% -39.0%
Mar 18 2.5 0.90 2.48 0.8% 5.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.